Dr. Hays is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2050 Kenny Rd
Tower 8th Floor
Columbus, OH 43221Phone+1 614-293-6529Fax+1 614-293-9469
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2005 - 2008
University of Texas Medical Branch School of MedicineClass of 2005
Certifications & Licensure
OH State Medical License 2012 - 2026
MD State Medical License 2008 - 2012
NC State Medical License 2005 - 2008
Clinical Trials
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Start of enrollment: 2014 May 20
- A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2018 Oct 25
Publications & Presentations
PubMed
- 50 citationsThe role of PARP inhibitors in the treatment of gynecologic malignanciesRaquel E. Reinbolt, John L. Hays
Frontiers in Oncology. 2013-10-01 - 32 citationsCD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient TumorsGiovanni Germano, Steve Lu, Giuseppe Rospo, Simona Lamba, Benoit Rousseau
Cancer Discovery. 2021-03-02 - 26 citationsA phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safetyJohn L. Hays, Geoff Kim, Amanda J. Walker, Christina M. Annunziata, Jung-Min Lee
Molecular and Clinical Oncology. 2013-05-01
Journal Articles
- The Omics Revolution Continues: The Maturation of High-Throughput Biological Data SourcesJames L Chen, John L Hays, Yearbook of Medical Informatics
- Loss of TXNIP Enhances Peritoneal Metastasis and Can Be Abrogated by Dual TORC1/2 InhibitionDavid Cohen, James L Chen, John L Hays, Oncotarget
- Early closure for safety: A phase II clinical trial of polyethylene glycol conjugated L-asparaginase in patients with advanced ovarian cancer6. Hays, J.L., Kim, G., Annunziata, C.M., Lee, J-m. Squires, J., Houston, N., and Kohn, E.C., Molecular and Clinical Oncology, 3/20/2013
Press Mentions
Dr. Hays on Immunotherapy in Ovarian Cancer TreatmentJanuary 14th, 2020
Foundation DonationMarch 2nd, 2017
NCCN Awards Research Grants to Eight Investigators to Support Clinical and Pre-Clinical Studies of Mirvetuximab Soravtansine in Various CancersJune 6th, 2016- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
